1,10-Diisopropyl-triethylentetramin | 24426-12-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1,10-Diisopropyl-triethylentetramin
• 英文别名: 1,2-Ethanediamine, N,N'-bis(2-((1-methylethyl)amino)ethyl)-；N,N'-bis[2-(propan-2-ylamino)ethyl]ethane-1,2-diamine
• CAS: 24426-12-8
• 化学式: C₁₂H₃₀N₄
• 分子量: 230.397
• InChiKey: XEJHFUWIGVKNNO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  16
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  48.1
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  三乙烯四胺 、 丙酮 在 platinum(IV) oxide 氢气 作用下， 生成 1,10-Diisopropyl-triethylentetramin
  参考文献：
  名称：

  Gelbard,G.; Rumpf,P., Bulletin de la Societe Chimique de France, 1969, p. 1161 - 1170

  摘要：

  DOI：

文献信息

• Crosslinkers for improving stability of polyurethane foams
  申请人：Vedage Gamini Ananda

  公开号：US20080090922A1

  公开（公告）日：2008-04-17

  A composition for making a polyurethane foam includes a non-fugitive tertiary amine urethane catalyst and an alkylated polyamine crosslinking additives. Foams prepared from the reaction of a polyol and an organic isocyanate in the presence of these ingredients show improved resistance to deterioration of physical properties upon humid aging.

  一种制备聚氨酯泡沫的配方包括非挥发性三级胺脲催化剂和烷基化聚胺交联添加剂。在这些成分的存在下，聚醚和有机异氰酸酯反应制备的泡沫在湿度老化时显示出改善的物理性能耐久性。
• RNA interference in ocular indications
  申请人：Phio Pharmaceuticals Corp.

  公开号：US10662430B2

  公开（公告）日：2020-05-26

  The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.

  本发明涉及 sd-rxRNA 和 rxRNAori 分子的眼部给药。
• Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
  申请人：Phio Pharmaceuticals Corp.

  公开号：US10808247B2

  公开（公告）日：2020-10-20

  In one aspect, the disclosure provides methods for treating a neurodegenerative disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule and a therapeutically effective amount of a small molecule that activates NF-κB p65 and increases expression of manganese superoxide dismutase (MnSOD/SOD2) and/or expression of a related protein or enzyme.

  在一个方面，本发明公开了治疗神经退行性疾病的方法，包括向有需要的受试者施用治疗有效量的核酸分子和治疗有效量的小分子，该小分子可激活NF-κB p65并增加锰超氧化物歧化酶（MnSOD/SOD2）的表达和/或相关蛋白或酶的表达。
• Encapsulation
  申请人：The Procter & Gamble Company

  公开号：US10864167B2

  公开（公告）日：2020-12-15

  An improved process of making a benefit agent delivery particle and consumer products incorporating such particles are disclosed. The process comprises the steps of providing a first composition of water phase 1, water phase 2 and water phase 3. Water phase 1 comprises water and an initiator; water phase 2 comprises water, a water-soluble or dispersible amine(meth)acrylate or hydroxyl(meth)acrylate and a multifunctional (meth)acrylate. Water phase 3 comprises water, and carboxyalkyl(meth)acrylate and a base or quaternary ammonium acrylate. The first two water phases are combined to prereact the hydroxy- or amine(meth)acrylate and the multifunctional (meth)acrylate to form a multifunctional hydroxyl-amine(meth)acrylate pre-polymer. The pre-polymer is combined with water phase 3; then an emulsion is formed by emulsifying under high shear agitation a second composition into said first composition; said second composition comprising an oil phase comprising an isocyanate and a benefit agent core material thereby forming a wall surrounding the benefit agent core material.

  本发明公开了一种改进的益处剂输送颗粒制造工艺和含有这种颗粒的消费品。该工艺包括以下步骤：提供由水相 1、水相 2 和水相 3 组成的第一种组合物。水相 1 由水和引发剂组成；水相 2 由水、水溶性或分散性甲基丙烯酸胺或甲基丙烯酸羟基酯和多功能（甲基）丙烯酸酯组成。水相 3 包括水、羧基烷基（甲基）丙烯酸酯和碱或丙烯酸季铵。将前两相水合并，使羟基或胺（甲基）丙烯酸酯和多功能（甲基）丙烯酸酯发生预反应，形成多功能羟基-胺（甲基）丙烯酸酯预聚物。将预聚物与水相 3 结合；然后在高剪切搅拌下将第二种组合物乳化到所述第一种组合物中，形成乳液；所述第二种组合物包括由异氰酸酯组成的油相和益处剂芯材，从而形成围绕益处剂芯材的壁。
• Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)
  申请人：Phio Pharmaceuticals Corp.

  公开号：US11001845B2

  公开（公告）日：2021-05-11

  Aspects of the invention relate to methods for treating ALS comprising administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule that is directed against a gene encoding superoxide dismutase 1 (SOD1).

  本发明的各个方面涉及治疗 ALS 的方法，包括向有需要的受试者施用治疗有效量的核酸分子，该核酸分子针对编码超氧化物歧化酶 1 (SOD1) 的基因。